HiberGene Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Out of Business

  • Employees
  • 12


  • Latest Deal Type
  • Liquidation

HiberGene General Information


Developer of real-time molecular diagnostic tests designed to test for the direct detection of human infectious diseases. The company's tests utilize loop-mediated isothermal amplification, performed on a small, portable, and low-cost platform, enabling clinicians to diagnose their disease in near-patient settings such as clinical laboratories, emergency rooms, and delivery wards producing.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Corporate Office
  • Block 2, Bracken Business Park
  • Sandyford
  • Dublin D18 RR24
  • Ireland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HiberGene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Bankruptcy: Liquidation 12-Sep-2022 000.00 Completed Bankruptcy: Liquidation
8. Later Stage VC 21-Dec-2020 00.000 000.00 00.000 Completed Generating Revenue
7. Grant Cancelled Generating Revenue
6. Grant 20-May-2020 00.000 000.00 Completed Generating Revenue
5. Later Stage VC 21-Dec-2018 00.000 000.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series B) 12-Apr-2017 00.000 00.00 000.00 Completed Generating Revenue
3. Grant 10-Feb-2016 000.00 00.000 Completed Generating Revenue
2. Later Stage VC (Series A) 01-Dec-2014 $2.64M $2.64M 00.000 Completed Generating Revenue
1. Spin-Off 01-Jan-2009 Completed Generating Revenue
To view HiberGene’s complete valuation and funding history, request access »

HiberGene Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 00.000000 00000.00 00000.00 00 00000.00 00.00
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 1,151 $0.012069 $1486.28 $1486.28 1x $1486.28 8.74%
Ordinary 20 $0.012069 $1474.45 $1474.45 1x $1474.45 0.15%
To view HiberGene’s complete cap table history, request access »

HiberGene Comparisons

HQ Location
Total Raised
Post Valuation
Developer of real-time molecular diagnostic tests designed to test for the direct detection of human infectious diseases
Diagnostic Equipment
Dublin, Ireland
12 As of 2022
000000000000 000.00

0000 0

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000000000 000000000
Nehren, Germany
00 As of 0000
000.00 0000-00-00

00 000

r in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
0000000000 000000000
Lexington, MA
000 As of 0000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HiberGene Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hain Lifescience Corporate Backed or Acquired Nehren, Germany 00 000000&0
T2 Biosystems Formerly VC-backed Lexington, MA 000 00000 00000000 00000
Advanced Molecular Diagnostics Corporation Nottingham, United Kingdom 0
QuantaMatrix Formerly VC-backed Seoul, South Korea 000 000.00 00000000 000.00
Atomo Diagnostics Formerly VC-backed Leichhardt, Australia 00 000.00 00000000 000.00
You’re viewing 5 of 34 competitors. Get the full list »

HiberGene Patents

HiberGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201919067-D0 Biological sample testing device Inactive 20-Dec-2019
GB-201820681-D0 Biological sample testing device Inactive 19-Dec-2018
GB-201721219-D0 Biological sample testing device Inactive 18-Dec-2017

HiberGene Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HiberGene FAQs

  • When was HiberGene founded?

    HiberGene was founded in 2009.

  • Who is the founder of HiberGene?

    Brendan Farrell, Peter Kidney, and Derek Fairley Ph.D are the founders of HiberGene.

  • Where is HiberGene headquartered?

    HiberGene is headquartered in Dublin, Ireland.

  • What is the size of HiberGene?

    HiberGene has 12 total employees.

  • What industry is HiberGene in?

    HiberGene’s primary industry is Diagnostic Equipment.

  • Is HiberGene a private or public company?

    HiberGene is a Private company.

  • What is HiberGene’s current revenue?

    The current revenue for HiberGene is 00000.

  • How much funding has HiberGene raised over time?

    HiberGene has raised $16.9M.

  • Who are HiberGene’s competitors?

    Hain Lifescience, T2 Biosystems, Advanced Molecular Diagnostics, QuantaMatrix, and Atomo Diagnostics are some of the 34 competitors of HiberGene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »